Illumina is trading now at $215.64, up 5.19%, following investor enthusiasm after Moderna and Merck’s positive Phase 3 personalized mRNA cancer-vaccine results sparked a broad biotech rally.
- Illumina rose 8.87% on August 19.
- Biotech is cooling on August 20; today’s additional strength may also reflect momentum from Illumina’s recent earnings beat and raised 2026 outlook.